Seres Therapeutics, Inc., a microbiome therapeutics platform company, focuses on the development of biological drugs designed to restore health by repairing the function of a dysbiotic microbiome. Its lead product candidate is SER-109, a bacterial spore ecology, which has completed open label Phase Ib/2 clinical study for the prevention of further recurrences of Clostridium difficile infection (CDI). The company also develops SER-287 that is in phase Ib clinical study to treat inflammatory bowel disease, including ulcerative colitis. Its product candidates in pre-clinical development comprise SER-262, an Ecobiotic microbiome therapeutic designed to be used following antibiotic treatment of primary CDI; and SER-155 for the prevention of transplant-related mortality. Seres Therapeutics, Inc. has a strategic collaboration with Nestle Health Science and Memorial Sloan Kettering Cancer Center; and a collaboration agreement with the University of Pennsylvania. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
Seres Therapeutics stock tanks 78% after 'unexpected' negative midstage trial results Seres Therapeutics Inc. MCRB, -75.48% shares cratered 78% in pre-market trade Friday after the company said interim phase 2 trial results for its colon infection treatment weren't statistically significant. The company's chief executive officer, Roger Pomerantz, called the results "unexpected" in light of a previous phase 1b trial and other supporting data. The treatment, SER-109, is intended for multiply recurrent Clostridium difficile infection, which is commonly spread in hospitals and other health care institutions.
